ArticleCureus2025
Fever of Unknown Origin Unveiling Bone Marrow Necrosis Secondary to Diffuse Large B-cell Lymphoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Morphologic Obscurity to Diagnostic Clarity in Bone Marrow Necrosis: A Clinicopathological Approach to Diagnosis and Etiological Assessment.Iranian journal of pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone marrow necrosis (BMN) is a very rare pathological finding that may arise in the context of numerous underlying conditions. It has been linked to hematologic malignancies, solid tumors, sickle cell disease, various infections, and certain medications. Advances in hematopathology have contributed significantly to the improved identification and diagnostic accuracy of BMN. We report a case of a 75-year-old woman who was evaluated for anemia and fever of unknown origin. Histopathological examination of a bone marrow biopsy revealed widespread necrosis accompanied by infiltration with diffuse large B-cell lymphoma (DLBCL). Positron emission tomography (PET)/computed tomography (CT) showed pathologic uptake in the skeletal system and in multiple lymph node regions, on both sides of the diaphragm. Following treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), a repeat bone marrow biopsy demonstrated persistent, complete BMN, whereas a subsequent PET/CT scan revealed complete metabolic response of the lymphoma, indicating a discordance between remission of lymphoma and the persistence of BMN. A comprehensive literature review was performed, and the clinical features of our patient were compared with data from previously published studies. The patient exhibited several characteristics commonly observed in the literature, including fever, anemia, and elevated lactate dehydrogenase (LDH) levels. However, the patient did not present with thrombocytopenia or a leukoerythroblastic peripheral smear. According to existing literature, the primary prognostic factor for patients with BMN is the effective control of the underlying disease. However, in our case, while remission of lymphoma was achieved, it was not associated with improvement in BMN. Areas for further discussion and advancement in the understanding of the etiology, diagnosis, and management of BMN are also highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.